Suppr超能文献

齐多夫定与获得性免疫缺陷综合征的自然史

Zidovudine and the natural history of the acquired immunodeficiency syndrome.

作者信息

Moore R D, Hidalgo J, Sugland B W, Chaisson R E

机构信息

Johns Hopkins University School of Medicine, Department of Health and Mental Hygiene, Baltimore, MD.

出版信息

N Engl J Med. 1991 May 16;324(20):1412-6. doi: 10.1056/NEJM199105163242006.

Abstract

BACKGROUND AND METHODS

We sought to describe the trends in survival from 1983 to 1989 among persons with the acquired immunodeficiency syndrome (AIDS) and to examine the relative effects on the natural history of AIDS of zidovudine use and demographic and clinical characteristics. This longitudinal, observational, population-based study used data from the Maryland Human Immunodeficiency Virus Information System, a data base that links information from the Maryland AIDS Registry with data on public and private health care claims, vital statistics, and hospital, long-term care, and ambulatory care records.

RESULTS

The median survival after diagnosis among persons with AIDS (n = 1028) was 140 days longer for those given their diagnoses between 1987 and 1989 than for those given their diagnoses between 1983 and 1985 (450 vs 310 days). Among the 714 persons in whom AIDS was diagnosed after April 1987 (when zidovudine became available), two-year survival was greater among men than women (P less than 0.03), among persons less than 45 years old than among older persons (P less than 0.001), among non-Hispanic whites than among minorities (P less than 0.001), and among persons whose category of human immunodeficiency virus transmission was homosexual contact than among those with heterosexual, transfusion-related, or less common modes of transmission (P less than 0.02). In all the analyses the groups with the longer survival were more likely to have received zidovudine. The median survival among those who received zidovudine was 770 days, as compared with 190 days among those who never received the drug (P less than 0.001). By proportional-hazards analysis, zidovudine therapy was the factor most strongly associated with improved survival.

CONCLUSIONS

For Maryland residents with AIDS there has been an improvement in survival since 1987. Zidovudine therapy and perhaps other aspects of care associated with it have contributed substantially to the improved survival.

摘要

背景与方法

我们试图描述1983年至1989年期间获得性免疫缺陷综合征(AIDS)患者的生存趋势,并研究齐多夫定的使用以及人口统计学和临床特征对AIDS自然史的相对影响。这项基于人群的纵向观察性研究使用了马里兰州人类免疫缺陷病毒信息系统的数据,该数据库将马里兰州艾滋病登记处的信息与公共和私人医疗保健索赔、生命统计以及医院、长期护理和门诊护理记录的数据相链接。

结果

艾滋病患者(n = 1028)中,1987年至1989年确诊的患者诊断后的中位生存期比1983年至1985年确诊的患者长140天(450天对310天)。在1987年4月(齐多夫定上市)后确诊艾滋病的714人中,男性的两年生存率高于女性(P<0.03),45岁以下人群高于年长人群(P<0.001),非西班牙裔白人高于少数族裔(P<0.001),人类免疫缺陷病毒传播途径为同性恋接触的人群高于异性恋、输血相关或其他较不常见传播方式的人群(P<0.02)。在所有分析中,生存期较长的组更有可能接受过齐多夫定治疗。接受齐多夫定治疗的患者中位生存期为770天,而从未接受该药物治疗的患者为190天(P<0.001)。通过比例风险分析,齐多夫定治疗是与生存率提高最密切相关的因素。

结论

自1987年以来,马里兰州艾滋病患者的生存率有所提高。齐多夫定治疗及其相关的其他护理方面对生存率的提高有很大贡献。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验